EAGLET: EEG vs aEEG to Improve the Diagnosis of neonataL Seizures and Epilepsy (EAGLET)
Neonatal Seizures
About this trial
This is an interventional diagnostic trial for Neonatal Seizures focused on measuring Neonatal Seizures, cEEG, aEEG, Epilepsy
Eligibility Criteria
Inclusion Criteria:
- Term or preterm neonate, born at post-menstrual age (PMA) 32-44 weeks;
And at least one of the following:
(2.1) Neonate with any clinical event suspicious of seizures (2.2) Neonate at high-risk of seizures with confirmed or suspected: (2.2.1) Hypoxic ischaemic encephalopathy (moderate to severe, or deemed eligible for therapeutic hypothermia) (2.2.2) Cerebral vascular insult (e.g., perinatal arterial ischaemic stroke, cerebral venous sinus thrombus) (2.2.3) Meningitis / encephalitis - Inflammatory (2.2.4) Inborn error of metabolism (2.2.5) Brain malformation (2.2.6) Large intraventricular haemorrhage (III-IV)
- Infant is up to 28 days of age
- Written informed parental consent can be obtained.
Exclusion Criteria:
- No parental consent
- Poor prognosis of immediate survival
- Any contraindication to perform EEG (e.g. structural pathologies interfering with EEG electrode placement, such as cephalohematoma or subgaleal haemorrhage).
- Infants born at less than 31+6 weeks PMA and infants who are or are suspected to be experiencing or are at high-risk of seizures when aged 29 days or older.
Sites / Locations
- Cambridge University Hospitals NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Group A is a control group with aEEG monitoring only, and with retrospective cEEG review
Group B is undergoing aEEG monitoring with concurrent full EEG review